NASDAQ
162.93USD
-4.06 (-2.43%)
We have scored 9 news catalysts on Twist Bioscience Corporation (TWST) over the past 12 months. The biggest single-day move next to one of them came Aug 5, 2026, when TWST closed +15.6%: “Conestoga Micro Cap Composite Q2 2026 Leaders, Laggards, Buys And Sells”. Coverage across the window leans positive (average ticker sentiment +0.44). Most of the impact sits in sector healthcare and revenue growth rate.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
10.2B
P/E
—
EPS
—
Beta
2.22
52W range
23.3-170.23
Day range
160.62–170.23
Open
168.40
Prev close
166.99
Volume
1.4M
Avg volume
1.8M
Dividend
0.00
IPO
2018-10-31
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Twist Bioscience Corporation — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for TWST: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
